DNA-methylation and genomic copy number in primary tumors and corresponding lymph node metastases in prostate cancer from patients with low and high Gleason score

Unger, Kristian; Heß, Julia; Link, Vera; Büchner, Alexander; Eze, Chukwuka; Li, Minglun; Stief, Christian G.; Kirchner, Thomas; Klauschen, Frederick; Zitzelsberger, Horst; Niyazi, Maximilian; Ganswindt, Ute; Schmidt-Hegemann, Nina-Sophie; Belka, Claus

doi:10.1016/j.ctro.2023.100586

Cited by 1 publication

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, patients with GS < 8 exhibited higher frequencies of EM and CM cells and lower frequencies of TEMRA cells compared with patients having GS ≥ 8. Intratumoral analyses in localized PCa linked increased immunosuppression and epigenetic modifications leading to compromised immunity with high GS [26,27]. Thus, peripheral biomarkers comprising high frequencies of CM and EM cells, as well as low ones of TEMRA cells, seem to correlate with lower tumor load (non-metastatic disease) and lower tumor aggressiveness (lower GS levels), whereas the opposite is true for the inverse subset frequencies (i.e., links to metastatic disease and higher tumor aggressiveness by low CM, EM and high TEMRA frequencies).…”

Section: Discussionmentioning

confidence: 99%

Peripheral Blood CD8+ T-Lymphocyte Subsets Are Associated with Prognosis in Prostate Cancer Patients

Baxevanis

Stokidis

Goulielmaki

et al. 2023

Onco

View full text Add to dashboard Cite

Background: Various studies have reported associations between frequencies of total peripheral blood lymphocytes and prostate cancer prognosis, but none so far has addressed the prognostic role of CD8+ T-lymphocyte subsets. Methods: A total of 43 prostate cancer patients with metastatic disease and 81 patients with non-metastatic disease were included in this study. Flow cytometry analyses were employed for determining the frequencies of peripheral CD8+ T-lymphocyte subsets. Results: Statistically significant lower levels of terminally differentiated effector (TEMRA) cells in patients with non-metastatic disease vs. patients with metastatic disease were observed. Central memory (CM) and effector memory (EM) CD8+ subsets, were found to be significantly higher in patients with non-metastatic disease vs. patients with metastatic disease. A similar profile was revealed when these CD8+ subsets were analyzed based on the patients’ Gleason scores, as well as by combined disease stage (i.e., non-metastatic vs. metastatic disease) and Gleason score. Conclusions: Peripheral blood-derived CD8+ T-lymphocyte memory subsets could function as biomarkers for the prognosis of PCa.

show abstract

Section: Discussionmentioning

confidence: 99%